Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Bepreve in Healthy Volunteers
NCT00586625Phase 3Completed
- Sponsor
- Bausch + Lomb
- Start
- Oct 2007
- Primary completion
- May 2008
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in allergic conjunctivitis (AC) comparing Bepreve with Placebo (2 arms). Primary endpoint: Ocular Comfort at 22 days. Started Oct 2007; status: completed.
02
Drugs
bepotastine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT00586625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00586625.